A
A
A

ViiV Healthcare将在2026年艾滋病大会上展示Dovato和Biktarvy的IIIb期临床试验数据

·in 4 hours发布

  • VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy in treatment-naïve adults living with HIV

  • Real-world OPERA data continues to strengthen the evidence base for Cabenuva, the only complete long-acting injectable HIV treatment regimen

  • Six-month results from the CLARITY study will report participant experience and acceptability of long-acting cabotegravir versus lenacapavir injections after a single dose in HIV-negative adults

 

21 July 2026--GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its integrase strand transfer inhibitor (INSTI)-focused portfolio, including long-acting (LA) medicines and pipeline momentum, to be presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from 26-31 July.

 

VOGUE daily orals phase IIIb data will compare ViiV Healthcare’s established 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in treatment-naïve adults living with HIV1

  • Additional data from VOGUE will examine the study population demographics, including adults with high viral loads.2

  • A pooled analysis across clinical trials will examine on-study viraemic events and outcomes for DTG/3TC compared with 3-drug regimens.3

 

Data evaluating long-acting injectable HIV treatment, including late-breaking LATA results and OPERA real-world data, will add to the evidence base for cabotegravir + rilpivirine long acting (CAB+RPV LA)

  • Late-breaking week 96 results from the LATA study, led by University College London, will evaluate the efficacy, safety and acceptability of CAB+RPV LA versus daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in virologically suppressed adolescents living with HIV across sub-Saharan Africa.4

  • New data from OPERA will be presented, including from the US-based cohort, comparing the virologic effectiveness of injectable CAB+RPV LA versus daily oral BIC/FTC/TAF in virologically suppressed adults living with HIV.5,6,7

  • Week 96 results from the IMPALA study, led by London School of Hygiene and Tropical Medicine, will provide new insights into the use of CAB+RPV LA in adults living with HIV with prior adherence challenges in sub-Saharan Africa, including treatment outcomes over time.8

  • Data from Ask Us Europe, a community co-produced survey, led by an academic team in London, will explore whether people living with HIV across Europe are having meaningful and equitable conversations with healthcare providers about long-acting HIV treatment options.9,10,11

 

CAB LA for pre-exposure prophylaxis (PrEP) data, including CLARITY results comparing CAB LA with lenacapavir, will inform how long-acting injectable prevention options are used in practice

  • Six-month results from the phase I CLARITY study will report participant experience and acceptability of CAB LA versus lenacapavir injections after a single dose, as well as late-breaking data on participant-reported outcomes, informing decision-making when initiating long-acting injectables for PrEP.12,13

  • CAPTIVATE results will describe real-world use, acceptability and delivery of CAB LA for PrEP in routine US clinical practice.14,15

  • Updated PrEPFACTS results will describe real-world use and adherence patterns for CAB LA for PrEP in the US, using healthcare administrative claims data.16

 

EXTEND 4M will evaluate a new long-acting dosing candidate for HIV prevention

  • Baseline data from the phase IIb registrational EXTEND 4M trial will describe the population being evaluated in the first study evaluating a new formulation of CAB LA dosed three times a year for HIV PrEP.17 This study builds on the established evidence for CAB LA for PrEP dosed six times a year and will assess the pharmacokinetics, safety and tolerability of the new CAB LA formulation.

 

About Cabenuva (cabotegravir + rilpivirine)

 

Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

 

The complete regimen combines the INSTI cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Johnson & Johnson. Rilpivirine tablets are approved in the US and when used with cabotegravir is indicated for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

 

INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse transcriptase, which stops the virus from multiplying.

 

About Dovato (dolutegravir and lamivudine)

 

Dovato is indicated for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25 kg in the US, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

 

Please consult the full Summary of Product Characteristics for all the safety information: Dovato 50 mg/300 mg film-coated tablets.

 

About Apretude (cabotegravir long acting)

 

Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir.

 

Please consult the full Summary of Product Characteristics for all the safety information: Apretude 600 mg prolonged-release suspension for injection

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

 

About ViiV Healthcare

 

ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

 

About GSK

 

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. 

 

References

  1. J Ghosn, et al. In VOGUE: DTG/3TC 2-drug regimen is non-inferior to BIC/FTC/TAF 3-drug regimen in a randomized trial in adults with HIV naive to treatment. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  2. F Pulido, et al. Who’s in VOGUE: A Head-to-Head Clinical Trial of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults Naive. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  3. P Cahn et al. Pooled analysis of on-study viremic events (VEs) and outcomes for dolutegravir + lamivudine (DTG+3TC) and comparator 3-drug regimens (3DRs) in clinical trials of people with HIV-1. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  4. M. B. Dangarembiz, et al. Eight-weekly injectable cabotegravir and rilpivirine is superior to daily oral tenofovir disoproxil fumarate/lamivudine/dolutegravir in adolescents living with HIV in sub-Saharan Africa: LATA 96-week results. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  5. R. Hsu, et al. Comparable virologic effectiveness with long-acting cabotegravir + rilpivirine vs. daily bictegravir/emtricitabine/tenofovir alafenamide in the US-based OPERA Cohort. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  6. J. Altamirano, et al. Resuppression and resistance after confirmed virologic failure among women on CAB+RPV LA in the OPERA Cohort. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  7. C. Millner, et al. High virologic suppression among individuals on cabotegravir + rilpivirine long-acting with viral loads ≥50 copies/mL regardless of body mass index in the OPERA Cohort. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  8. E. Ruzagira, et al. Long-acting cabotegravir and rilpivirine in adults with suboptimal HIV control in sub-Saharan Africa: the IMPALA trial 96-week results. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  9. M. Devonald, et al. Perspectives of people living with HIV in Europe on their clinical consultations: an equity analysis. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  10. M. Devonald, et al. Interest of people living with HIV in Europe in future long-acting modalities-Ask Us Europe results. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  11. M. Devonald, et al. Complex support needs, adherence challenges and interest in long-acting HIV treatment among trans, non-binary, and gender-diverse people living with HIV: findings from the coproduced ‘Ask Us Europe’ survey. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  12. L. Dupont-Benjamin, et al. Presence, Severity, Interference With Usual and Daily Life Activities and Bothersomeness of Injection Site Reactions With Cabotegravir vs Lenacapavir: Insights From Participant Reported Outcomes in the CLARITY Study. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  13. K. L. Nelson, et al. Participant and Provider Experiences With Long-Acting Cabotegravir vs Lenacapavir Injections: Results From the CLARITY Study. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  14. M. Brizzi, et al. Real-world experience using cabotegravir long-acting for HIV-1 pre-exposure prophylaxis in the united states from cross-sectional surveys and retrospective chart reviews: results from the CAPTIVATE study. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  15. K. Visnyei, et al. Operational insights for long-acting cabotegravir for HIV-1 pre-exposure prophylaxis: findings from the CAPTIVATE United States healthcare provider survey. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  16. G. F. Herman, et al. Real-world utilization and adherence of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States: Updated results from the PrEPFACTS study using healthcare administrative claims data. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

  17. C. Acuipil, et al. Baseline demographics in the phase 2b registrational EXTEND 4M trial: evaluating a novel every-4-month cabotegravir formulation in a population who could benefit from PrEP. Presented at the 26th International AIDS Conference (AIDS 2026). July 2026.

文章关键词： ViiV Healthcare艾滋病DovatoBiktarvy
下载PDF
0
发布文章
0
关注人数